Fairvalue-Calculator Fairvalue-Calculator
EN DE

Fulcrum Therapeutics, Inc (FULC) Fair Value & Analysis

Healthcare · US · Market cap $247M

Price$3.76
Fair Value$9.39
Upside+149.7%
Quality95/100
Evidence: Low Range $6.11 – $11.47

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Fulcrum Therapeutics, Inc (FULC) currently trades at $3.76, while our model-based Fair Value estimate is $9.39 — implying the stock looks roughly 149.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Fulcrum Therapeutics, Inc (FULC) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $9.39 versus a price of $3.76 — about +150% (undervalued). Model-based estimate, not financial advice.
What is the fair value of FULC?
Our 21-model fair value for Fulcrum Therapeutics, Inc is $9.39 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.76.
What is the quality score of FULC?
Fulcrum Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.